Heterocyclic compounds and metal coordination complexes constitute two important classes of molecules in contemporary medicinal chemistry because of their structural diversity, tunable physicochemical properties, and broad spectrum of biological activities. The incorporation of heteroatom-containing rings into bioactive molecular frameworks can enhance molecular recognition, solubility, lipophilicity, and interaction with biological targets, whereas coordination with metal ions can introduce additional mechanisms of biological action, including redox modulation, DNA interaction, enzyme inhibition, mitochondrial dysfunction, and generation of reactive oxygen species. This review discusses recent developments in the synthesis, characterization, and anticancer evaluation of heterocyclic compounds and their metal coordination complexes. Conventional and modern synthetic approaches, including cyclization, condensation, Schiff-base formation, multicomponent reactions, and ligand-assisted metal coordination, are examined. Characterization using Fourier-transform infrared spectroscopy, nuclear magnetic resonance spectroscopy, ultraviolet-visible spectroscopy, mass spectrometry, elemental analysis, thermal analysis, and single-crystal X-ray diffraction provides essential information regarding molecular structure and coordination geometry. Particular attention is given to transition-metal complexes containing ruthenium, platinum, copper, cobalt, nickel, zinc, and palladium, as well as biologically relevant heterocyclic scaffolds such as imidazole, thiazole, triazole, pyridine, quinoline, indole, benzimidazole, and quinazoline. Their anticancer potential is discussed in relation to cytotoxicity, apoptosis induction, cell-cycle arrest, oxidative stress, DNA binding, and inhibition of cancer-associated enzymes and signaling pathways. The review also highlights challenges associated with selectivity, toxicity, solubility, pharmacokinetics, and clinical translation. Rational ligand design, combination strategies, nanotechnology-assisted delivery, and mechanism-based screening may facilitate the development of next-generation heterocyclic and coordination compounds with improved anticancer efficacy and selectivity.
